Indefinite Delivery Contract 75D30125D20479
Award Date
7/1/25
Last Date to Order
6/30/26
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to supply a variety of adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The total contract ceiling value is $232,487,206.61. The contract covers the procurement of an estimated 1.5 to 3 million doses of 12 different adult vaccines, including hepatitis A, hepatitis B, hepatitis A &...
The indefinite delivery contract (IDC) 75D30120D08572 was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC for the provision of vaccines for adults. The $131,225,875 multiple award contract has a period of performance through June 30, 2021. Glaxosmithkline, a pharmaceutical company, will supply a range of vaccines and antiviral medications to support disease prevention efforts, immunization programs, and healthcare services for various U.S. government...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to provide a wide range of pediatric vaccines over a period of performance from April 1, 2024 to March 31, 2025. The contract has a ceiling value of $1,334,738,300 and is part of the CDC's National Center for Immunization and Respiratory Diseases (NCIRD) effort to support pediatric immunization programs under...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC to procure a variety of adult vaccines over a 1-year period from July 1, 2021 to June 30, 2022. The $156,027,900 multiple award IDC contains no set-aside designation and requires delivery within 15 business days of order placement to destinations across the United States to support state health departments and immunization programs. The original solicitation...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency, to Glaxosmithkline Holdings (Americas) Inc. as the prime contractor. The contract has a ceiling value of $261,469,025.27 and a period of performance ending on June 30, 2011. The purpose of this IDC is to provide adult vaccines, as part of the CDC's Adult Vaccine Contract 2010 - 2011 program. The contract was not set aside for any specific business category. It was...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide adult influenza vaccines for the 2024-2025 season. The $13,916,000 multiple award IDC has a period of performance through February 28, 2025. The contract does not have any set-aside designations. Glaxosmithkline will likely provide the vaccines from its facilities in North Carolina to support the CDC's immunization programs...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to the pharmaceutical company Glaxosmithkline, LLC to provide pediatric influenza vaccines for the 2024-2025 timeframe. The contract has a ceiling value of $182,592,000 and a period of performance through February 28, 2025. Glaxosmithkline, a foreign-owned for-profit organization, has extensive experience as a prime contractor providing a range of pharmaceutical products and services to...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
The federal contract IDV awarded to Glaxosmithkline, LLC is a $83,834,950 Indefinite Delivery Contract to provide a range of adult vaccines to the Centers for Disease Control and Prevention (CDC) for a period of performance through June 30, 2019. The single-award contract was issued without any set-aside designation. The contract aims to procure various pharmaceutical products and immunization services to support public health initiatives, including influenza vaccines, hepatitis vaccines,...
The federal contract IDV award is for the procurement of pediatric flu vaccines by the Centers for Disease Control and Prevention (CDC) Pittsburgh, a civilian agency. The prime contractor is Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company that specializes in vaccines, antiviral medications, and other medical countermeasures. The contract has a ceiling value of $182,592,000.00 and a period of performance from December 31, 2024 to February 28, 2026. It is a multiple award,...